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Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic disorder leading
to end-stage renal failure in humans. In the PKD/Mhm(cy/+) rat model of ADPKD, the point mutation R823W in the
sterile alpha motif (SAM) domain of the protein ANKS6 is responsible for disease. SAM domains are known
protein-protein interaction domains, capable of binding each other to form polymers and heterodimers. Despite its
physiological importance, little is known about the function of ANKS6 and how the R823W point mutation leads to
PKD. Recent work has revealed that ANKS6 interacts with a related protein called ANKS3. Both ANKS6 and ANKS3
have a similar domain structure, with ankyrin repeats at the N-terminus and a SAM domain at the C-terminus.
Results: The SAM domain of ANKS3 is identified as a direct binding partner of the ANKS6 SAM domain. We find that
ANKS3-SAM polymerizes and ANKS6-SAM can bind to one end of the polymer. We present crystal structures of both
the ANKS3-SAM polymer and the ANKS3-SAM/ANKS6-SAM complex, revealing the molecular details of their association.
We also learn how the R823W mutation disrupts ANKS6 function by dramatically destabilizing the SAM domain such
that the interaction with ANKS3-SAM is lost.
Conclusions: ANKS3 is a direct interacting partner of ANKS6. By structurally and biochemically characterizing the
interaction between the ANKS3 and ANKS6 SAM domains, our work provides a basis for future investigation of how
the interaction between these proteins mediates kidney function.
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Autosomal dominant polycystic kidney disease (ADPKD)
is the most common inherited renal cystic disease, with
a prevalence of approximately 1 in 1,000 individuals
[1-3]. ADPKD is characterized by the progressive forma-
tion of fluid-filled cysts within the kidney which ultim-
ately disrupt renal function, as well as various extrarenal
manifestations [3,4]. Mutations in two genes, PKD1
(polycystic kidney disease-1) and PKD2 (polycystic kidney
disease-2) account for approximately 85% and 15% of
disease cases, respectively [2]. The occurrence of dis-
ease in patients lacking mutations in either of these genes* Correspondence: bowie@mbi.ucla.edu
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unless otherwise stated.suggests the involvement of other genetic loci, but this is
still uncertain [5]. PKD1 and PKD2 encode the proteins
polycystin-1 (PC1) and polycystin-2 (PC2), respectively.
PC1 is a multidomain membrane receptor capable of bind-
ing and interacting with proteins, lipids, and carbohydrates
and stimulating intracellular signaling pathways. PC2 is a
membrane protein which acts as a Ca2+-permeable non-
selective cation channel. PC1 and PC2 can interact, and in
the process, modulate each other’s activity [2,6].
Among the animal models of polycystic kidney disease,
the PKD/Mhm(cy/+) rat recapitulates many of the hall-
marks of human ADPKD [7-10]. The Cy mutation was
found to be a missense mutation in the ANKS6 gene, en-
coding ankyrin repeat and SAM-domain containing pro-
tein 6 (ANKS6) [11]. Human ANKS6 is an 871 amino acid
protein containing 11 ankyrin repeats at its N-terminus
and a SAM domain near its C-terminus (Figure 1A). The
Cy mutation occurs in the SAM domain and generates anl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 The ANKS3 and ANKS6 proteins. A) The domain structure of human ANKS3 and human ANKS6. ANK = ankyrin repeat, SAM = sterile
alpha motif, Ser-rich = serine rich region, helical = potential coiled coil domain. B) The sequences of the human ANKS3-SAM [UniProt:Q6ZW76]
and ANKS6-SAM domains [UniProt:Q68DC2] used in this work. The top numbering is the numbering used in the crystal structures. Each sequence
contains an additional Ser at the N-terminus that is not shown. The numbers in bold below each sequence correspond to the numbering in the
full length proteins.
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The R823W point mutation acts in a dominant-negative
fashion, as evidenced by the PKD phenotype of transgenic
rats over-expressing mutated ANKS6(p.R823W) [12].
Recently ANKS6 has also been implicated in human
renal disease. In particular, the work Hoff and Halbritter
et al. [13] has placed ANKS6 as a central node in a net-
work of nephronophthisis (NPHP)-associated proteins,
including direct binding between the ankyrin-repeat do-
main of ANKS6 and NEK8, a NimA (never in mitosis A)-
related serine-threonine kinase which is mutated in
nephronophthisis. Moreover, 8 individuals from 6 differ-
ent families bearing homozygous mutations in ANKS6 all
presented with nephronophthisis, which is essentially an
infantile or juvenile onset of PKD [13]. While several of
the detected mutations localize to the ankyrin repeats,
one generates a truncation within the SAM domain
at Tyr790. Thus, the SAM domain has been shown
in both rats and humans to be essential for normal ANKS6
function.
SAM domains consist of approximately 70 amino acids
and adopt a globular structure generally containing a core
of five α-helices [14,15]. Most SAM domains that have
been characterized are protein-protein interaction modules
that either self-associate [16-22], bind to other SAM-
domain containing proteins [14,23-27], or bind other pro-
teins altogether [14,28,29]. Some SAM domains have been
found to bind RNA and lipids, however [30,31]. The
protein-protein interactions of SAM domains are typically
mediated by two distinct surfaces on the domain, termed
the mid-loop (ML) and end-helix (EH) surfaces. SAMs can
bind each other via their ML and EH surfaces, to generate
open-ended polymers [16,18,19,24,32], closed oligomers
[23,24], and heterodimers [24,27,33,34]. Through polymerformation and heterotypic interactions, SAM domains
confer a diverse array of biological functions including
gene regulation [18,24], enzyme localization [16,35], and
scaffolding [19,20,36].
In spite of the important role of the ANKS6-SAM do-
main in cystic kidney disease, the function of ANKS6 re-
mains unknown. Prior work using a proteomics screen of
tandem affinity purified (TAP)-tagged NPHP-associated
proteins found that ANKS6 and ankyrin repeat and SAM-
domain containing protein 3 (ANKS3) are potential
binding partners [13]. ANKS3 has a similar domain
structure to ANKS6 including a C-terminal SAM domain
(Figure 1A). Here we define the ANKS6/ANKS3 inter-
action by discovering that the ANKS6 SAM domain binds
to the SAM domain of ANKS3. We show that ANKS3-
SAM forms polymers and that ANKS6 binds to one end
of these polymers. The R823W mutation was found to dis-
rupt the structure of the ANKS6 SAM domain and nega-
tively affects binding to ANKS3-SAM. Our results provide
a structural explanation for the defect in PKD/Mhm(cy/+)
rats and a potential new pathway to cystic disease via the
SAM domain of ANKS3.
Results
negGFP native gel screen identifies ANKS3-SAM + ANKS6-
SAM interaction
To identify new human SAM domain hetero-interactions
involving ANKS3, we employed a rapid screen for binding
activity, outlined in Figure 2A. SAM domains were fused
to an engineered green fluorescent protein modified to
have a net charge of −30 (negGFP) [22,37]. The high
charge on the negGFP effectively solubilizes even insoluble
proteins, and leads to consistent migration of the fusion
proteins towards the cathode on a native gel [22]. Binding
Figure 2 ANKS3-SAM binds to ANKS6-SAM. A) Schematic of the negGFP native gel binding assay. Lysate containing a negGFP-human-SAM fusion
protein is mixed with lysate containing a negGFP fusion of a different human SAM domain. Each SAM domain contains an ML-surface (red) and
an EH-surface (blue). Mixes and individual SAM controls are run on native gels and visualized by fluorescence. Novel hetero-SAM interactions appear
as a new upshifted band (asterisk) in the gel schematic. B) negGFP fusions of ANKS6-SAM, ANKS3-SAM, and a 1:1 mix of ANKS6-SAM + ANKS3-SAM
assayed by native gel electrophoresis. ANKS6-SAM appears monomeric, ANKS3-SAM appears weakly polymeric, and the appearance of a new
distinct band upon mixing the proteins indicates an interaction.
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pearance of a new band with retarded migration on native
gels. Because the fusions are fluorescent, assays can be per-
formed using crude extracts. Thus, many different combi-
nations of proteins can be rapidly screened using this
technique.
Extract containing negGFP-ANKS3-SAM fusion protein
was mixed with extracts containing negGFP-SAM fusions
from 40 different human SAM domain-containing proteins
(Additional file 1) and binding was tested by native gel elec-
trophoresis. Among the human SAMs assayed, we detected
a novel interaction between ANKS3-SAM and ANKS6-
SAM (Figure 2B). Consistent with prior results, negGFP-
ANKS6-SAM appears monomeric as it runs as a discrete
band with migration similar to other monomeric SAM do-
mains [22]. In contrast, the negGFP-ANKS3-SAM fusion
runs as a more diffuse band with slightly slower migration,
behavior that was observed previously and is typical ofweakly polymeric SAM domains [22]. When negGFP-
ANKS3-SAM and negGFP-ANKS6-SAM were mixed in a
1:1 ratio, the appearance of a new slower migrating species
indicates that ANKS3-SAM and ANKS6-SAM bind to each
other. We therefore decided to investigate the polymeric
character of ANKS3-SAM and the novel ANKS3-SAM+
ANKS6-SAM hetero-interaction further.ANKS3-SAM is polymeric
We first chose to characterize the ANKS3-SAM domain
and investigate whether ANKS3-SAM forms a polymer.
In a prior screen for SAM polymers, negGFP-ANKS3-
SAM was observed by negative stain transmission electron
microscopy (TEM) to form short polymeric structures
[22]. We re-examined the negGFP-ANKS3-SAM fusion
and obtained results consistent with earlier work, showing
short polymers 11.4 ± 2.2 nm wide on average and varying
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proximately 36 nm (Figure 3A).
Since the addition of negGFP in the SAM fusion pro-
teins introduces charge repulsion that weakens SAM do-
main interaction and polymerization, we next examined
the ANKS3-SAM domain by itself. Without the negGFP
fusion, ANKS3-SAM was much less soluble and precipi-
tated after purification. We examined the precipitate by
TEM and saw enormous sheets of polymers, some extend-
ing more than 1 μm long and 0.4 μm wide (Figure 3B-D).
Individual polymers within the fiber-like sheets were ap-
proximately 4–6 nm wide. The ability of SAM domains to
organize as sheets of polymers has been seen previously
with the SAM domains of DGKδ and Shank3 [19,35], how-
ever it is unclear whether sheet formation is physiologically
relevant for ANKS3-SAM.
Mapping the ANKS3-SAM polymer
To determine the interfaces of ANKS3-SAM responsible
for polymer formation, we employed our negGFP binding
assay to rapidly screen for point mutants that blocked
polymerization. A similar approach was used in our previ-
ous study of the Caskin1 tandem SAM domains [20]. We
targeted putative ML and EH surface residues to find
those that yielded faster migration on a native gel. As
shown in Figure 4A, the mutations D31K, I36E and E47K
on the ML-surface and L52E, F53E and K58E on the EH-
surface inhibited polymerization. Thus, ANKS3-SAM ap-
pears to form a polymer using an interface common to
other SAM polymers [14].
The identification of monomeric ANKS3-SAM mutants
allowed us to measure binding affinity between subunits
using surface plasmon resonance (SPR). To measure affin-
ity of the native interface, we immobilized an ANKS3-
SAM EH-surface mutant, F53E, on an SPR chip and
detected equilibrium binding to an ML-surface mutant,
I36E. At 0.15 M NaCl, we observe hyperbolic binding with
a Kd of 5.8 ± 0.4 μM (Figure 4D). As many of the muta-
tions that reduce polymerization involve charged residues,
we also examined the salt dependence of binding. As
shown in Figure 4F, where the salt sensitivity of a protein-Figure 3 ANKS3-SAM assembles into polymers. A) Negative stain TEM
(arrows). B-D) His6-tagged ANKS3-SAM (negGFP removed) precipitates as laprotein interaction is indicated by the slope of a log Kd
versus log [salt] plot [38,39], the binding affinity is indeed
strongly dependent on salt concentration.
Structure of the ANKS3-SAM polymer
To better understand how the ANKS3-SAM domain
forms polymers we sought a crystal structure of the poly-
mer. Because the wild-type SAM domain is relatively insol-
uble, forming heterogeneous polymers, it cannot be
crystallized directly. We therefore used a strategy that has
proven successful for a number of other SAM domain
polymers, where we attempt to crystallize SAM domains
with mutations in the polymer interface [16,18,24]. The
mutations weaken subunit association so that the protein
remains soluble during purification but under the high
concentrations required for crystallization, the polymer
interface remains a favorable site for crystal contacts,
thereby generating the polymer in the crystal.
We were able to obtain a crystal structure of the L52A
mutant (Figure 5). ANKS3-SAM L52A crystallized in
space group P41 with two molecules in the asymmetric
unit and the structure was solved to 1.6 Å resolution.
Each SAM domain has the characteristic five α-helical
fold and chains in the asymmetric unit are nearly identi-
cal (RMSD of 0.29 Å on backbone atoms and 0.3 Å on
all atoms). Examination of the crystal packing reveals a
triple helix of intertwined SAM polymers (Figure 5A).
Individual SAM polymers contain 8 SAMs per helical
repeat, with each helical repeat measuring 72 Å in diam-
eter and 100 Å in length. As expected from the muta-
tional studies described above, the ANKS3 SAM domains
associate via sequential interactions of ML and EH
surfaces (Figure 5B). The ML-surface, formed by resi-
dues spanning loop 2 through helix 4, is composed
of a shallow hydrophobic patch (residues V32, I36,
L40, and I48) flanked by negatively charged residues
(D31, D33, D44, E47). The EH-surface encompasses
the N-terminal portion of helix 5 and contains a crit-
ical Phe (F53) which packs against the hydrophobic
patch of a neighboring ML-surface. Several positively
charged residues (K22, K56, R57, K58) surround F53,of the negGFP-ANKS3-SAM fusion protein reveals short helical polymers
rge fibrous sheets of polymers.
Figure 4 Characterizing the ANKS3-SAM polymer interface and the ANKS3-SAM/ANKS6-SAM interaction interface. A) The negGFP native
gel screen identifies point mutations in both the EH- and ML-surfaces of ANKS3-SAM that result in a loss of polymeric character. Point mutations
in ANKS6-SAM do not impact the native gel migration or monomeric character of this SAM domain. B) Mixing negGFP-ANKS3-SAM and
negGFP-ANKS6-SAM mutants in 1:1 molar ratios reveals that the EH-surface of ANKS3-SAM binds the ML-surface of ANKS6-SAM. Point mutations on
the EH-surface of ANKS3-SAM inhibit interaction with ANKS6-SAM whereas point mutations on the ML-surface of ANKS3-SAM do not affect the
hetero-interaction. Point mutations on the ML-surface of ANKS6-SAM and the Cy mutation (R54W according to our numbering) inhibit interaction
with ANKS3-SAM. C) ANKS3-SAM precipitate is resolubilized by the addition of ANKS6-SAM but not by the addition of buffer alone. D) The binding
affinity of the native ANKS3-SAM polymer interface is measured by SPR (Kd = 5.8 ± 0.4 μM). Equilibrium binding measurements were performed in
triplicate and fit to a 1:1 steady-state model. The calculated Kd is an approximation since tested analyte concentrations were insufficient to reach
saturation. The error bars are smaller than the data points. E) The binding affinity of the native ANKS3-SAM/ANKS6-SAM interface is measured by
SPR (Kd = 249 ± 8 nM). Equilibrium binding measurements were performed in triplicate and fit to a 1:1 steady-state model. The error bars are smaller
than the data points. F) The binding between both ANKS3-SAM/ANKS3-SAM and ANKS3-SAM/ANKS6-SAM exhibits a salt dependency. The Kd
of each interaction was determined by SPR at four different ionic strengths. The slope of the linear fit (~2 for ANKS3-SAM/ANKS6-SAM, ~1
for ANKS3-SAM/ANKS3-SAM) indicates that each interface is salt-dependent and employs ionic interactions.
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negative charge on a neighboring ML-surface through
the formation of salt bridges (K22 + D31, K56 + E47,
R57 + D44). The striking asymmetric charge distribution
is consistent with the strong salt dependence of subunit
association (see above).
The crystal structure is consistent with the identified
polymer-blocking mutants (Figures 4A and 5B). F53E
removes a key hydrophobic contact of the EH-surface
and I36E introduces steric overlap and disruption of the
ML-surface. The L52A mutation used in the crystal
structure is found at the end of helix 5 and appears
to remove van der Waals packing and complementary
hydrophobic surface at the interface. The mutations
D31K and E47K remove ionic interactions. Finally, K58
was also found crucial for polymerization and althoughit does not form a direct salt bridge in the crystal struc-
ture, this residue is near the interface and helps to main-
tain charge complementarity. It is also possible that the
interface is altered somewhat in the mutant structure,
weakening and/or breaking some salt bridges. The width
of the single polymer (~7 nm) is thicker than the polymers
seen by TEM (4–6 nm) but SAM domain polymers are
known to stretch and compact readily in different crystal
forms [40].
Individual ANKS3-SAM polymers pack in the crystal
structure as a striking triple helix, but we do not know if
this is a biologically relevant structure. Caskin1, which
also contained 8 SAMs per helical polymer repeat,
adopted a triple helix in the crystal, but it was shown to
likely be an artifact of crystallization [20]. The N- and
C-termini do splay out from the triple helix, so the
Figure 5 Structure of the ANKS3-SAM L52A mutant. A) ANKS3-SAMs pack as a triple helix approximately 72 Å in diameter and 100 Å long per
helical repeat. In the side view of the triple helix, two separate polymer chains are shown as cartoons (grey and black) and the third is shown as
a space-filled model colored by surface electrostatics calculated using APBS in Pymol and contoured at ±1 kT/e; red is negatively charged and
blue is positively charged. Looking down the polymer axis (left and right) and viewing only the surface electrostatics of a single polymer for clarity
reveals the charge complementarity of the polymer surface. B) A single ANKS3-SAM homodimer is shown. Helices have been numbered 1–5. Side
chains of residues found critical for the EH-and ML-surface in the negGFP binding assay are shown colored in blue and red, respectively. Both the
EH- and ML-surfaces are shown colored by surface electrostatics calculated using APBS and contoured at ±1 kT/e, revealing the charge complementarity
of the binding interface.
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accommodated. Moreover, there is charge comple-
mentarity between polymer surfaces. In particular, the
polymer surface viewed from the free ML-surface end
(Figure 5A right) has negative patches which comple-
ment the positive patches seen from the free EH-surface
end (Figure 5A left). Unlike the inter-polymer association
seen in the Caskin1 structure which was largely mediated
by an added His6-tag, the triple helix of ANKS3-SAM is
held together by residues Ala3-Gly7 of chain A (for
which there is no equivalent density in chain B) intercal-
ating between SAM polymers of an adjacent triple helix
(Additional file 2). Nevertheless, the polymers are not
packed tightly, as there are ample gaps between individ-
ual polymers.
The phenomenon of ANKS3-SAM polymer sheet for-
mation observed by TEM also remains to be tested in
the context of the full-length protein. Sheets of triple
helices can be constructed from the crystal structure,
but the sheets formed in the crystal packing (Additional
file 2) would be incompatible with triple helix formation.
Although the N- and C- termini extend away from the
triple helix polymer axis, additional domains of the full-
length protein cannot be obviously accommodated in
the sheets. If sheets do form as seen in the EM images,it would require different packing than we see in the
crystal structure.
The EH-surface of ANKS3-SAM binds the ML-surface of
ANKS6-SAM
To map the binding interface between ANKS3-SAM and
ANKS6-SAM, we employed the negGFP binding assay
discussed above. As shown in Figure 4B, mutations in
residues L52, F53, and K58 on the EH-surface of ANKS3-
SAM and mutations in residues E29 and D42 on the
ML-surface of ANKS6-SAM abolish the ANKS3-SAM+
ANKS6-SAM hetero-interaction in this assay.
Since the EH-surface of ANKS3-SAM is required for
both polymerization and binding to ANKS6-SAM, these
two events are mutually exclusive. Therefore, ANKS6-
SAM binding to ANKS3-SAM should block ANKS3-
SAM polymerization. To test this possibility, we mixed
ANKS6-SAM with the insoluble ANKS3-SAM polymer
described above. As shown in Figure 4C, the addition of
ANKS6-SAM does indeed lead to solubilization of the
ANKS3-SAM precipitate.
The ability of ANKS6-SAM to solubilize ANKS3-SAM
polymers and the slower migration of the hetero-
interaction on the native gel compared to ANKS3-SAM
suggests that ANKS6-SAM has a higher affinity for
Leettola et al. BMC Structural Biology 2014, 14:17 Page 7 of 15
http://www.biomedcentral.com/1472-6807/14/17ANKS3-SAM than ANKS3-SAM does for itself. To
determine the affinity of the ANKS3-SAM/ANKS6-SAM
interface we again used SPR by immobilizing ANKS6-
SAM and measuring equilibrium binding to an ANKS3-
SAM ML-surface mutant, I36E. At 0.15 M NaCl, we
observed a high binding affinity (Kd = 249 ± 8 nM)
(Figure 4E). This affinity is more than an order of magni-
tude tighter than the binding affinity we measured for
the native EH-ML interface formed between ANKS3-
SAMs (Kd = 5.8 ± 0.4 μM), indicating that ANKS6-SAM
binding could effectively compete with polymerization.
Binding is also strongly salt dependent as shown in
Figure 4F, suggesting that ionic interactions are important
features of the interface.
Structure of the ANKS3-SAM/ANKS6-SAM complex
To learn how ANKS3-SAM and ANKS6-SAM bind each
other, we determined a crystal structure of the complex
(Figure 6A). To prevent ANKS3-SAM polymerization
without destroying ANKS6-SAM binding, we mixed an
ML-surface mutant of ANKS3-SAM, I36E, with wild-
type ANKS6-SAM. These proteins formed a heterodimer
when analyzed by SEC-MALS (Figure 6B) and yielded
crystals suitable for structure determination.Figure 6 Structure of the ANKS3-SAM/ANKS6-SAM heterodimer. A) Th
the individual SAM domains are numbered 1–5. Side chains of residues wh
respectively. Each surface is also colored by surface electrostatics calcu
complementarity of the binding interface. B) SEC-MALS analysis of a 1
a single monodisperse peak with a calculated molecular weight of 16.8 k
C) Alignment of an ANKS3-SAM homodimer (grey) with the ANKS3-SAM/AN
atoms of the common ANKS3-SAMs. I36 in ANKS3-SAM is changed to A34 in
and form more interactions.The ANKS3-SAM/ANKS6-SAM heterodimer crystallized
in space group C2221 with four molecules (2 ANKS3-SAM
I36E mutants and 2 ANKS6-SAMs) per asymmetric unit.
Both of the ANKS3-SAM chains and both ANKS6-SAM
chains in the asymmetric unit had closely similar structures,
with RMSDs between backbone atoms of 0.279 Å and
0.169 Å, respectively. Additionally, the overall structure of
ANKS3-SAM I36E aligns well with ANKS6-SAM (RMSD
across backbone atoms is 0.626 Å) with the only obvious
difference being a 1.6 Å outward shift of ANKS6-SAM’s
helix 3.
Similar to the ML-surface of ANKS3-SAM, the ML-
surface of ANKS6-SAM contains a shallow hydrophobic
patch (residues V30, A34, L38, L46) flanked by negatively
charged residues (E29, D31, E33, D42, E45) (Figure 6A).
Many of these charged residues form salt bridges with
ANKS3-SAM (ANKS6 E29 +ANKS3 K22, ANKS6 D31 +
ANKS3 K58, ANKS6 D42 +ANKS3 R57). Other residues
of ANKS6-SAM (E33, E45) form hydrogen bonds with
ANKS3-SAM bridged by water. These results are consist-
ent with our native gel analysis of critical interface residues
(Figure 4B). Similar to the ANKS3-SAM/ANKS3-SAM
interface, the F53E mutation in ANKS3-SAM removes
a Phe required for packing against the hydrophobice ANKS3-SAM EH-surface binds the ANKS6-SAM ML-surface. Helices of
ich form the ML- and EH-surface are shown and colored red and blue,
lated using APBS and contoured at ±1 kT/e, revealing the charge
:1 molar ratio mix of ANKS3-SAM I36E + ANKS6-SAM wt produces
Da, which corresponds to a homogenous population of heterodimer.
KS6-SAM heterodimer (blue-green), formed by aligning the backbone
ANKS6-SAM, which allows ANKS6-SAM to tilt closer to ANKS3-SAM
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mutation removes van der Waals interactions and hydro-
phobic contacts that otherwise stabilize the interaction
interface. Removal of salt bridges by the mutations K58E
in ANKS3-SAM, E29K in ANKS6-SAM, and D42K in
ANKS6-SAM also break the interface. The ANKS6-SAM
mutation R54W (R823W in the full length protein) breaks
the interaction with ANKS3-SAM as well and will be dis-
cussed below.
Comparing an ANKS3-SAM/ANKS6-SAM heterodi-
mer with an ANKS3-SAM homodimer by aligning the
ANKS3-SAMs, we see that ANKS6-SAM is tilted closer
towards ANKS3-SAM (Figure 6C). This ANKS3-SAM/
ANKS6-SAM interface buries on average 454 Å2 of sur-
face area, which is approximately 100 Å2 more than was
buried at the same interface in the ANKS3-SAM poly-
mer. An isoleucine (I36) in ANKS3-SAM is switched for
an alanine (A34) in ANKS6-SAM at the ML-surface.
The decreased steric bulk of Ala compared to Ile allows
helix 3 of ANKS6-SAM’s ML-surface to approach the
EH-surface of ANKS3-SAM more closely, resulting in
the burial of additional surface area and the formation of
more salt bridges and hydrogen bonds, which may ex-
plain the higher affinity of the ANKS3-SAM/ANKS6-
SAM interface. The ANKS6-SAM structure also shows
that the EH-surface is lacking a large hydrophobic residue
flanked by positively charged residues, thereby showing
that ANKS6-SAM cannot polymerize because its EH-
surface is incompatible with binding its ML-surface.
The R823W mutation of Pkd/Mhm(cy/+) rats perturbs the
structure of ANKS6-SAM
Using our native gel binding assay, we discovered that
the Cy mutation (R54W in our numbering of the construct,
R823W in the full-length protein) in ANKS6-SAM de-
stroys the interaction with ANKS3-SAM (Figure 4B).
This interaction could not be restored by titrating increas-
ing amounts of ANKS6-SAM R823W with ANKS3-SAM
(Figure 7A). To understand how the Cy mutation might be
responsible for disease in Pkd/Mhm(cy/+) rats, we exam-
ined its position in our structure of ANKS6-SAM. R823
(R54 in the crystal structure numbering, see Figure 1)
forms salt bridges with D51 of helix 5 and D40 of helix 4,
and forms hydrogen bonds with the backbone carbonyls of
I48 and K49 which both lie on a loop between helices 4
and 5 (Figure 7B). Through these interactions, R54 is in-
volved in stapling helices 4 and 5 and in maintaining the
overall fold in this segment of the domain.
Since the R823W mutation does not lie on either the
ML- or EH-surface of ANKS6-SAM, we reasoned that
its ability to abolish binding to ANKS3-SAM must be
due to a long range structural alteration. Indeed the far-
UV CD spectrum of ANKS6-SAM R823W shows an ap-
proximately 10% loss of helical structure with a parallelincrease in random coil compared to the wild-type pro-
tein (Figure 7C). Moreover, the stability of the protein is
dramatically reduced. As shown in Figure 7D, wild-type
ANKS6-SAM displayed a broad, reversible unfolding
curve with a Tm of approximately 48°C. In contrast,
the ANKS6-SAM R823W mutant strikingly exhibited
a complete loss of cooperative unfolding. Therefore, the
R823W mutation appears to dramatically destabilize the
structure. The mutant protein also migrates slightly faster
and with a higher molecular weight as assessed by SEC-
MALS (Additional file 3), consistent with generalized
unfolding. Indeed, modeling a tryptophan at position R54
in our structure is impossible as this would introduce se-
vere steric clashes. Thus, coupling the removal of Arg
with the insertion of a Trp disturbs the overall tertiary
structure of the protein and prevents the ML-surface of
the ANKS6-SAM domain from adopting a fold comple-
mentary to binding the ANKS3-SAM domain.
Discussion
The PKD/Mhm(cy/+) rat, in which an R823W mutation
in the SAM domain of ANKS6 is causal of disease, has
been used extensively as an animal model for the study
of human ADPKD. However, the underlying mechanism
whereby this single mutation leads to improper kidney
development and loss of renal function has been unclear.
For the first time, we have identified the SAM domain of
ANKS3 as a direct binding partner of the ANKS6-SAM
domain and shown that this interaction is lost in the
ANKS6-SAM R823W mutant. The physiological rele-
vance of this interaction is supported by the independent
identification of the potential ANKS3/ANKS6 inter-
action in a proteomics screen [13].
By solving the crystal structure of ANKS3-SAM, we
have observed that ANKS3-SAM forms polymers via se-
quential interactions of ML- and EH-surfaces, much like
other SAM domains. The polymer formation by ANKS3-
SAM suggests that ANKS3 may be capable of scaffolding a
larger protein complex. We also observed higher order
structure of the polymer, including a triple helix in the
crystal and sheet structures in TEM images, but the bio-
logical relevance of these polymer associations is unclear.
SAM domains have been previously found to organize as
sheets of polymers that require divalent metal cation bind-
ing to form [35,36], but we did not observe any obvious
metal binding sites in the ANKS3-SAM crystal structure.
By solving a crystal structure of the ANKS3-SAM/
ANKS6-SAM heterodimer, we observed that the EH-
surface of ANKS3-SAM binds the ML-surface of ANKS6-
SAM. We have also provided a molecular explanation for
the defect in the R823W mutation: it disrupts the tertiary
structure of the ANKS6-SAM domain and prevents the
ML-surface of ANKS6-SAM from adopting a conform-
ation capable of binding ANKS3-SAM. Because the EH-
Figure 7 Characterizing the Cy mutation. A) negGFP native gel assay of ANKS3-SAM, ANKS6-SAM wt and ANKS6-SAM R823W. A titration series
with a constant amount of ANKS3-SAM and increasing amount of ANKS6-SAM R823W is unable to restore the ANKS3-SAM/ANKS6-SAM interaction.
B) The Cy mutation (R54) according to our numbering is highlighted on the ANKS6-SAM crystal structure in orange. R54 forms salt bridges and
hydrogen bonds with nearby atoms to stabilize the fold in this part of the domain. C) CD spectra of ANKS6-SAM wt and ANKS6-SAM R823W.
The reduced CD signal at 222 nm and the shifted minima around 208 nm correlate with a loss of alpha-helical character and gain of random
coil. D) Thermal denaturation curves of ANKS6-SAM wt and ANKS6-SAM R823W monitored by CD signal at 222 nm. ANKS6-SAM wt exhibits a
broad, weakly cooperative unfolding curve with Tm approx. 48°C, while ANKS6-SAM R823W unfolding is completely uncooperative.
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either the ML-surface of ANKS3-SAM or the ML-surface
of ANKS6-SAM, we expect that ANKS6 may act as a poly-
mer capper [24,28]. It may shorten the ANKS3-SAM poly-
mers or it may simply recruit ANKS3 polymers to a larger
complex of proteins.
ANKS6 has been linked to Bicaudal-C1 (BICC1), a
protein that when mutated is responsible for disease in
the jcpk mouse model of ADPKD and the bpk mouse
model of ARPKD (autosomal recessive polycystic kidney
disease) [41,42]. ANKS6 and BICC1 have been shown to
co-immunoprecipitate and co-localize in inner medul-
lary collecting duct (IMCD) cells. An unidentified pro-
tein complex has been suggested to link ANKS6 to
BICC1, by binding both the ANKS6-SAM domain and a
strand of RNA to which the KH domains of BICC1 are
bound [42]. It is reasonable to suspect that ANKS3 may
also be part of a complex with ANKS6 and BICC1.
Transgenic overexpression of ANKS6(p.R823W) can gen-
erate a disease phenotype, indicating that ANKS6-SAM
R823W acts as a dominant negative [12]. A dominant
negative effect would be expected to arise from a gain
of function, yet the mutation clearly destabilizes thestructure of the SAM domain. A reasonable possibility is
that other domains on ANKS6 recruit it to a complex
[42], but the defective SAM domain fails to appropri-
ately recruit other proteins, such as ANKS3, leading to
defective function. Altered RXR-mediated signaling
pathways are observed in PKD/Mhm(cy/+) rats [43] and
ANKS6 has recently been placed as a central node in a
distinct NPHP-associated signaling network [13].
The recent finding of mutations in ANKS6 in individ-
uals presenting with polycystic kidney disease [13] has
catapulted this protein from relevance in an animal
model to having direct implications for human renal devel-
opment and function. Furthermore, the fact that one pa-
tient with a truncation in ANKS6 at the N-terminal end of
the SAM domain also presented with aortic stenosis, caus-
ing obstructive cardiomyopathy, implicates ANKS6 in car-
diac development and function [13]. Whether ANKS3 may
also have a role in cardiac development, via its link with
ANKS6, remains to be investigated. So far, ANKS3 is the
only direct binding partner of ANKS6 identified that is af-
fected by the R823W mutation. Our work provides a struc-
tural and biochemical basis for future work on ANKS3 and
its interaction with ANKS6.
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We have identified and characterized the novel inter-
action between the SAM domain of ANKS3 and the
SAM domain of ANKS6. ANKS3-SAM was found to be
capable of polymerization, although polymer formation
and binding to ANKS6 appear mutually exclusive, sug-
gesting ANKS6 may act as a polymer capper. The R823W
mutation associated with cystic kidney disease causes a
destabilization of the ANKS6 SAM domain which disrupts
binding to ANKS3. By structurally and biochemically char-
acterizing this new interaction we provide a foundation to
support continued research into how the ANKS3/ANKS6
interaction affects kidney function.
Methods
Cloning and mutagenesis
negGFP-human-SAM fusions and DNA used in cloning
were as described previously [22]. All human ANKS3-
SAM constructs contained residues 421–490 [UniProt:
Q6ZW76] and all human ANKS6-SAM constructs con-
tained residues 771–840 [UniProt:Q68DC2]. A His6-
tagged construct of ANKS3-SAM was generated by cloning
the human ANKS3-SAM sequence into a pET28 vector
(Novagen). A His6-tagged construct of ANKS6-SAM
was generated by cloning the ANKS6-SAM sequence
into a pBAD-HisA vector (Invitrogen). In both con-
structs, the residues MARHHHHHHSSG were added to
the N-terminus of each SAM to incorporate a His6-tag.
Hexahistidine small ubiquitin-like modifier (SUMO)
tagged constructs were generated by cloning the ANKS3-
SAM and ANKS6-SAM sequences into a pHis-SUMO vec-
tor [44]. Site-directed mutagenesis was performed using
the Quickchange method (Agilent). All plasmid sequences
were verified by DNA sequencing (Genewiz).
negGFP native gel binding assay
negGFP-human-SAM fusions transformed into ARI814
cells [45] were expressed as described previously [22].
Harvested cells were resuspended in 0.5 mL of 20 mM
Tris pH 7.5, 0.3 M NaCl, 2 mM TCEP, supplemented
with DNaseI (40 μg/mL), lysozyme (10 mg/mL), PMSF
(1 mM), MgCl2 (10 mM), and half a tablet of cOmplete
mini, EDTA-free protease inhibitor (Roche) and lysed by
three freeze-thaw cycles and one 10-sec. round of sonic-
ation. Lysate was centrifuged at 16,060 g for 20 minutes
at 4°C and the pellet discarded. The expression levels of
the negGFP-human-SAM fusions was determined by
fluorescence intensity as described previously [22]. To
identify new ANKS3-SAM interactions, lysates were mixed
to maintain equal amounts of negGFP-SAM fusion
(dilutions were made using 20 mM Tris pH 7.5, 0.3 M
NaCl, 1 mM TCEP). Mixes were allowed to equilibrate at
4°C for 3 hours, at which point 7.5 μL of 4X RunBlue
Native Sample Buffer (Expedeon) was added andsamples were applied to a 20% RunBlue 12-well Na-
tive gel in RunBlue Native Run Buffer (Expedeon) and
developed at 90 V for 24 hours at 4°C. Gels were visual-
ized on a Bio-Rad Molecular Imager FX Pro-Plus using
an excitation wavelength of 488 nm and an emission
wavelength of 510 nm. For characterization of ANKS3-
SAM and ANKS6-SAM mutants, lysates were prepared
as above and adjusted by fluorescence for equal gel load-
ing. Lysates were mixed in varying ratios based on fluor-
escence where appropriate, and allowed to equilibrate
at 4°C for 4 hours before gel loading. Gels were run at
90 V for 15 hours at 4°C and visualized as above.
Protein expression and purification
negGFP-ANKS3-SAM fusion
negGFP-ANKS3-SAM fusion transformed into ARI814
cells [45] was expressed as described previously [22].
Harvested cells were lysed as described previously, ex-
cept that 5 cOmplete mini, EDTA-free protease inhibitor
tablets (Roche) were included in the lysis buffer and five
1-min. rounds of sonication were used [22]. Following
centrifugation at 13,200 g for 20 minutes, lysate super-
natant was supplemented with 10 mM imidazole and
rocked with 2 mL of Ni-NTA Superflow agarose (Qiagen)
for 1 hour at 4°C. The resin was washed with lysis buffer
(20 mM Tris pH 7.5, 1 M NaCl, 1 mM TCEP) containing
20 mM imidazole, and eluted with lysis buffer containing
75 mM imidazole. Eluted protein was dialyzed into 20 mM
Tris pH 7.5, 0.15 M NaCl, 1 mM TCEP and loaded onto a
5 mL HiTrap Q HP column (GE) 4°C. Protein was eluted
using a shallow gradient of NaCl (0.25-0.5 M) in 20 mM
Tris pH 7.5, 1 mM TCEP. Purified protein was dialyzed
into 20 mM Tris pH 7.5, 0.3 M NaCl, 1 mM TCEP and
concentrated using an Amicon Ultra (10 kDa MWC0) cen-
trifugal filter unit (Millipore) to a final concentration of
4.3 mg/mL.
His6-tagged constructs
His6-tagged ANKS6-SAM was transformed into ARI814
cells and expressed as above in 6 L of LB media sup-
plemented with 100 μg/mL ampicillin. Harvested cells
were resuspended to 80 mL in lysis buffer (20 mM Tris
pH 8, 0.5 M NaCl) containing PMSF (1 mM), DNaseI
(20 μg/mL), and MgCl2 (10 mM) and lysed on an
EmulsiFlex-C3 (Avestin) at 18,000 psi. Lysate was centri-
fuged at 13,200 g for 20 minutes at 4°C. Supernatant, with
imidazole added to 10 mM, was bound at 4°C to a 5 mL
HiTrap IMAC HP column (GE) charged with NiCl2. The
column was washed with lysis buffer containing 20 mM
imidazole and eluted using a shallow gradient of imidazole
(20-260 mM). Eluted protein was diluted to approximately
1 mg/mL and dialyzed into 20 mM Tris pH 8.0, 50 mM
NaCl. Protein was further purified by loading onto a 1 mL
HiTrap Q column (GE) equilibrated in 20 mM Tris pH 8
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(0–1.0 M) in 20 mM Tris pH 8.0. Fractions containing
pure protein were dialyzed against 20 mM Tris pH 8.0,
0.3 M NaCl.
His6-tagged ANKS3-SAM was transformed into Rosetta
(DE3) cells (Novagen) and 4.5 L of culture was grown
in LB media supplemented with 30 μg/mL kanamycin
and 34 μg/mL chloramphenicol. Cells were grown at
37°C with shaking until cell density reached an OD600
of 0.7, at which point cells were chilled to 18°C, induced
with 1 mM isopropyl β-ᴅ-galactopyranoside (IPTG), and
grown an additional 16 hours at 18°C. Harvested cells were
resuspended to 80 mL in lysis buffer (20 mM Tris pH 7.0,
1 M NaCl, 2 mM BME) containing PMSF (1 mM), DNaseI
(20 μg/mL), MgCl2 (5 mM) and processed as above.
Supernatant, with imidazole added to 10 mM, was rocked
with 3 mL of Ni-NTA Superflow agarose (Qiagen) for
1 hour at 4°C. Resin was washed with 50 mL of lysis buffer
containing 10 mM imidazole, 200 mL of lysis buffer con-
taining 20 mM imidazole, and eluted using lysis buffer with
200 mM imidazole. Elution fractions were stored at 4°C
and developed fluffy precipitate overnight and for several
days thereafter.
SUMO-fusions
pHis-SUMO constructs (ANKS3-SAM mutants L52A,
F53E, I36E, and ANKS6-SAM wt and R823W) were trans-
formed into Rosetta(DE3) pLysS cells (Novagen) and 4 L
of culture was grown and expressed as described above.
Harvested cells were resuspended in lysis buffer (50 mM
NaHPO4 pH 8.0, 0.5 M NaCl, 2 mM BME) containing
PMSF (1 mM), DNaseI (20 μg/mL), and MgCl2 (5 mM)
and lysed on an EmulsiFlex-C3 (Avestin) at 18,000 psi
followed by centrifugation at 13,200 g for 20 minutes at
4°C. Supernatant, with imidazole added to 10 mM, was
rocked with Ni-NTA Superflow agarose (Qiagen) for
1 hour at 4°C. Resin was washed with lysis buffer con-
taining 20 mM imidazole and eluted with lysis buffer
containing 250 mM imidazole. The different proteins
were dialyzed into buffers of various ionic strengths as
required to maintain solubility: (1) ANKS3-SAM F53E
was dialyzed into 20 mM Tris pH 8.0, 0.3 M NaCl, 2 mM
BME; (2) ANKS6-SAM wt and R823W were diluted to
5-7 mg/mL and dialyzed into 20 mM Tris pH 8.0,
0.3 M NaCl; (3) ANKS3-SAM L52A and I36E were diluted
to 4-5 mg/mL and 50 mM EDTA was added to prevent
precipitation seemingly induced by leached Ni2+, followed
by extensive dialysis into 20 mM Tris pH 8.0, 0.5 M NaCl,
2 mM BME. To remove the His6-SUMO tag, all constructs
were digested with the His6-tagged catalytic domain of
SUMO protease 1 (ULP1) at a 50:1 protein:protease molar
ratio for 16 hours at 4°C [46]. The cleaved His6-SUMO tag
and ULP1 protease were removed by two rounds of sub-
tractive Ni-NTA. Here the protein was either in theflow-through (ANKS3-SAM F53E, ANKS6-SAM wt and
R823W) or remained weakly bound to the resin and was
eluted with 20 mM NaHPO4 pH 8.0, 0.5 M NaCl, 2 mM
BME, 10 mM imidazole (ANKS3-SAM L52A and I36E).
Final purification steps are specific to each construct as de-
scribed below.
ANKS3-SAM F53E
ANKS3-SAM F53E from the subtractive Ni-NTA flow-
through was dialyzed into 20 mM Tris pH 7.5, 30 mM
NaCl, 1 mM DTT and bound to a 5 mL HiTrap Q HP
(GE) column equilibrated in 20 mM Tris pH 7.5, 2 mM
DTT. Protein was eluted using a shallow gradient of
NaCl (0.1-0.5 M). Fractions containing pure ANKS3-
SAM F53E were dialyzed into 20 mM Tris pH 8.0, 50 mM
NaCl, 2 mM BME and concentrated in an Amicon
Ultra (3 kDa MWCO) centrifugal filter unit (Millipore)
to 27 mg/mL.
ANKS6-SAM wt and ANKS6-SAM R823W
ANKS6-SAM wt and R823W from the subtractive Ni-
NTA flow-through were each dialyzed into 20 mM Tris
pH 8.0, 50 mM NaCl and bound to a 5 mL HiTrap Q
HP column (GE) equilibrated in 20 mM Tris pH 8.0.
Protein was eluted with a shallow gradient of NaCl (0.1-
1 M). Pure fractions were pooled and dialyzed against
20 mM Tris pH 8, 0.15 M NaCl. Proteins were concen-
trated in Amicon Ultra (3 kDa MWCO) centrifugal filter
units to 12–14 mg/mL.
ANKS3-SAM L52A
ANKS3-SAM L52A exhibited a weak affinity for IMAC
resin and was dialyzed into 20 mM Tris pH 8.0, 0.5 M
NaCl, 2 mM BME and bound to a 5 mL HiTrap IMAC
HP column (GE) charged with NiSO4. Protein was
eluted using a shallow gradient of imidazole (0-15 mM).
Fractions containing pure ANKS3-SAM L52A were dia-
lyzed into 20 mM Tris pH 8.5, 0.15 M NaCl, 1 mM
DTT and concentrated using an Amicon Ultra (3 kDa
MWCO) centrifugal filter unit (Millipore) to approx.
5 mg/mL. Surprisingly, at this concentration the protein
spontaneously formed crystalline needles with low reso-
lution diffraction. Needles were resolubilized by the
addition of NaCl to a final concentration of 0.72 M.
ANKS3-SAM I36E
ANKS3-SAM I36E eluted from the subtractive Ni-NTA
column in both the flow-through and the 10 mM imid-
azole wash. The protein was dialyzed into 20 mM Tris
pH 8.0, 0.5 M NaCl, 2 mM BME and bound to a 5 mL
HiTrap IMAC HP column (GE) charged with NiSO4.
Protein was eluted using a shallow gradient of imid-
azole (0-15 mM). Pure fractions were pooled and di-
alyzed into 20 mM Tris pH 8.0, 0.75 M NaCl, 1 mM
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(3 kDa MWCO) centrifugal filter unit (Millipore) to
approx. 2.5 mg/mL.
Resolubilization of ANKS3-SAM precipitate by ANKS6-SAM
His6-tagged ANKS3-SAM precipitate was formed by dia-
lyzing protein at 3.2 mg/mL into low salt buffer (20 mM
Tris pH 7, 0.25 M NaCl, 1 mM DTT). His6-tagged
ANKS6-SAM at 3.3 mg/mL in 20 mM Tris pH 8.0,
0.3 M NaCl buffer or buffer alone (20 mM Tris pH 8.0,
0.3 M NaCl) was added in varying ratios of 2:1, 1:1, and
1:2 (ANKS3-SAM vs. ANKS6-SAM ratio) to the ANKS3-
SAM precipitate, keeping the total volume and total con-
centration of protein constant. Mixes were allowed to
incubate on ice for 3 hours.
Crystallization and structure determination
ANKS3-SAM L52A
Initial screening for crystallization conditions was per-
formed at the High Throughput Macromolecular Crys-
tallization Facility at UCLA. The crystallization trials were
carried out in hanging drops by vapor diffusion, using
commercially available screens and a Mosquito TTP crys-
tallization Robot.
Native crystals were grown by hanging drop vapor diffu-
sion by mixing 1μL of ANKS3-SAM L52A at 4.3 mg/mL
with 2μL of well solution (0.1 M Na/KPO4 pH 6.6, 0.3 M
NaCl, 15% PEG-8000). Rod-shaped crystals grew at 4°C
over a two-week period and were cryoprotected using well
solution supplemented with 25% glycerol. For phasing,
crystals were briefly soaked and cryoprotected (5 sec) in a
solution of 0.5 M KI prepared in well solution supple-
mented with 27% glycerol. A data set was collected for a
single ANKS3-SAM L52A iodide derivative crystal cryo-
cooled to 100 K at UCLA using the in-house RIGAKU
FRE + generator and HTC image plate detector at a
wavelength of 1.5418 nm. Data reduction and scaling were
performed using XDS/XSCALE [47]. Phasing was accom-
plished by single anomalous dispersion (SAD) using
the HKL2MAP interface and SHELX program [48,49].
Ten iodide atoms were detected and used for phasing.
Density modification and model building were accom-
plished using DM and BUCCANEER, respectively, in
the CCP4 suite [50]. The structure was briefly refined
in PHENIX [51] with inspection and model rebuilding
in COOT [52].
A high resolution data set was collected on a single
native crystal cryo-cooled to 100 K at the Advanced Pho-
ton Source (Argonne National Laboratory), APS-NECAT
beamline 24-ID-C on a DECTRIS-PILATUS 6 M de-
tector. Single crystals were mounted with CrystalCap
HT Cryoloops (Hampton Research, Aliso Viejo). A data
set containing 418 1.0° oscillation frames was collected
from a single large crystal at a wavelength of 0.9795 Å.This dataset was indexed and merged for scaling using
XDS [47]. The model was refined using PHENIX with
TLS parameterization including individual sites and indi-
vidual atomic displacement parameters [51]. Data collec-
tion and refinement statistics are reported in Table 1.
The coordinates have been deposited in the PDB with ac-
cession code 4NJ8.
ANKS3-SAM/ANKS6-SAM heterodimer
Crystals were grown in 2μL hanging drops by mixing
equal parts ANKS3-SAM/ANKS6-SAM heterodimer at
30 mg/mL (in 20 mM Tris pH 8.0, 0.15 M NaCl, 2 mM
BME) with 0.1 M Tris pH 8.0, 0.25 M MgCl2, 31.5%
PEG-4000 reservoir solution. Drops were allowed to
equilibrate overnight and were streak seeded the follow-
ing day using a cat whisker to transfer nuclei from crys-
tals that spontaneously formed overnight in a condition
with a higher percentage of PEG-4000. Seeded crystals
grew within one day and reached full size within 4 days.
An x-ray diffraction data set containing 300 1° oscilla-
tion frames was collected on a single crystal cryo-cooled
to 100 K at the Advanced Photon Source (Argonne
National Laboratory), APS-NECAT beamline 24-ID-C, at
a wavelength of 0.9793 Å and processed using XDS [47].
Molecular replacement was performed using PHASER
with ANKS3-L52A as a search model [54] and refined as
described above. Data collection and refinement statistics
are reported in Table 1. The coordinates have been de-
posited in the PDB with accession code 4NL9.
Structure analysis
Final structure models were validated with the following
structure validation tools: PROCHECK [55], ERRAT
[56], and VERIFY3D [57]. Graphics were prepared using
PyMOL [58]. Surface electrostatics were prepared using
the Adaptive Poisson-Boltzmann Solver (APBS) [59] plu-
gin in Pymol and all surfaces were contoured at ±1 kT/e.
Analysis of protein-protein binding interfaces was done
using the PISA server [60].
Circular dichroism
Spectra were collected for protein samples at 0.2 mg/ml in
10 mM Tris pH 8.0, 75 mM NaCl at 25°C on a JASCO J-
715 circular dichroism spectrophotometer equipped with
a Peltier temperature control. Spectra were analysed for
secondary structure content using the Selcon, Neural Net-
work, and Contin algorithms available in SoftSec (Soft-
wood Inc.). Thermal melts were performed by monitoring
the change in CD signal at 222 nm across a temperature
range of 25-80°C, with ramping of 1°C per minute.
Surface plasmon resonance
Experiments were performed at 21°C in 20 mM HEPES
pH 7.5, 1 mM DTT, 0.04% IGEPAL CA-630, and NaCl
Table 1 Crystallographic data collection and refinement
statistics
Iodide derivative
of ANKS3-SAM
L52A
ANKS3-SAM
L52A
ANKS3-SAM/
ANKS6-SAM
heterodimer
PDB Accession # 4NJ8 4NL9
Data collection
Location UCLA APS 24-ID-C APS 24-ID-C
Space group P41 P41 C2221
Cell dimensions
a, b, c (Å) 71.62, 71.62, 33.40 71.89, 71.89,
33.54
47.70, 108.52,
101.74
α, β, γ (°) 90.0, 90.0, 90.0 90.0, 90.0, 90.0 90.0, 90.0, 90.0
Resolution (Å) 2.34 1.60 1.50
Rsym 0.118 (.850) 0.087 (.804) 0.069 (.417)
I/σI 13.70 (2.62) 20.11 (5.40) 14.83 (4.16)
CC1/2 99.7 (74.0) 99.7 (91.7) 99.8 (89.9)
Completeness (%) 99.6 (95.2) 99.3 (99.3) 98.7 (96.9)
Redundancy 6.61 (5.84) 15.15 (15.01) 5.32 (4.94)
Phasing statistics
Number of sites 10
Mean figure of
merit
SAD/after density
modification
0.642/0.813
MapCC (SHELXE) 0.844
CC (%) 66.73
Refinement
Resolution (Å) 2.34 1.60 1.50
No. reflections 7333 22,797 42,203
Rwork/ Rfree 0.2709/0.3478 0.1975/0.2177 0.1798/0.2048
No. atoms
Protein 1030 1022 1952
Water - 50 246
Magnesium - - 1
B-factors (Å2)
Protein 36.70 37.42 21.92
Water - 38.73 28.94
R.m.s deviations
Bond lengths (Å) 0.011 0.006 0.005
Bond angles (º) 1.303 0.920 0.944
Highest resolution shell is shown in parenthesis.
Rsym = ∑ |I − < I > |/∑ < I >, where I is the observed intensity and <I> is the average
intensity from observations of symmetry-related reflections. CC1/2 = correlation
coefficient between two halves of the data [53]. Rwork = ∑ |Fobs – Fcalc|/∑Fobs, where
Fobs and Fcalc are the observed and calculated structure factor amplitudes,
respectively. Rfree is calculated for a set of reflections (10%) that were not included
in atomic refinement.
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termine the binding affinity of the ANKS3-SAM/ANKS6-
SAM interface, ANKS6-SAM wt was immobilized on a
Biacore CM5 chip (GE) via EDC/NHS crosslinking. To de-
termine the binding affinity of the ANKS3-SAM/ANKS3-
SAM interface, ANKS3-SAM F53E was immobilized on a
Biacore CM5 chip (GE) via EDC/NHS crosslinking. In
both cases, ANKS3-SAM I36E at varying concentrations
was passed over the chip and equilibrium binding levels
were measured. All data points were taken in triplicate and
binding data was fit to a 1:1 steady-state model using Bia-
core T100 Evaluation software. In total, 630.9 response
units (RUs) were immobilized on the ANKS6-SAM wt chip
surface and 2188.7 RUs were immobilized on the ANKS3-
SAM F53E chip surface. At 0.15 M NaCl, calculated Rmax
values were 262.7 for the ANKS6-SAM wt chip and 682.3
for the ANKS3-SAM F53E chip, indicating that 30-40% of
the surface molecules were active. To determine how ionic
strength impacted binding affinity, the ANKS3-SAM/
ANKS6-SAM Kd was determined at 0.15, 0.2, 0.25, and
0.3 M NaCl and the ANKS3-SAM/ANKS3-SAM Kd was
determined at 0.1, 0.15, 0.2, and 0.25 M NaCl. Prior to the
experiments, ANKS3-SAM I36E at 2.4 mg/mL was dia-
lyzed into 20 mM HEPES pH 7.5, 0.75 M NaCl, 1 mM
DTT, with the high salt required to maintain stability. Im-
mediately prior to each Biacore run, dilutions of ANKS3-
SAM I36E were prepared to match the running buffer and
protein concentration was determined by Bradford assay,
using known concentrations of ANKS3-SAM I36E for a
standard curve.Electron microscopy
Samples were applied to carbon/formvar coated copper
grids (Ted Pella, catalog number 01754-F) made hydro-
philic by glow discharge immediately before use and
allowed to bind for several minutes. Grids were rinsed
with distilled water and negatively stained with 1% uranyl
acetate. Samples were analysed on a CM120 transmission
electron microscope (TEM) operating at 120 kV. Images
were recorded using a TEITZ F224HD CCD camera and
processed using ImageJ (NIH).SEC-MALS
100 μL of protein (either ANKS3-SAM/ANKS6-SAM
heterodimer at 15 mg/mL, ANKS6-SAM wt at 10 mg/mL,
or ANKS6-SAM R823W at 10 mg/mL) was analysed by
SEC-MALS. Protein was loaded onto a WTC-030S5 ana-
lytical size-exclusion column (Wyatt Technology Co.)
equilibrated in 20 mM Tris pH 8.0, 0.15 M NaCl, (+2 mM
BME for the ANKS3-SAM/ANKS6-SAM heterodimer)
using an AKTA purifier (GE) and run at 0.5 mL/min
on a miniDAWN TREOS (Wyatt Technology Co.).
Eluted protein peaks were analysed for calculated
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ware (Wyatt Technology Co.)Additional files
Additional file 1: Human SAM domains screened for interaction
with ANKS3-SAM. negGFP-SAM-domain fusions of the following human
SAM-domain containing proteins were screened for binding to
negGFP-ANKS3-SAM using the negGFP native gel assay. Sequences of SAM
domains used and cloning are as described previously [22]. Where “2SAMs” is
listed, the construct contains two SAM domains in tandem.
Additional file 2: Crystal packing of ANKS3-SAM triple helices.
A) Individual ANKS3-SAM polymers intertwine to create a triple helix. Triple
helices pack side-by-side in the crystal structure. A single ANKS3-SAM triple
helix fills the unit cell, shown as a boxed outline. Individual polymers in
each triple helix are colored blue, grey, and black. A single polymer is
shown as a space-filled model colored by surface electrostatics generated
using APBS in Pymol and contouring at ± 1kT/e. Within a single ANKS3-SAM
polymer, the N-terminal arm (residues Ala3-Gly7) extends outward from every
other SAM domain in the helical segment and forms contacts with a
neighboring polymer of triple helices. B) Closer view of the N-terminal
arm swapping that occurs between polymers. Two polymers of triple
helices are shown, colored as above. Within each, a single polymer has
been removed for clarity. Residues Ala3-Gly7 intercalate between two
polymers of an adjacent triple helix, thereby forming crystal contacts
which stabilize the observed triple helix.
Additional file 3: Slight unfolding of ANKS6-SAM R823W observed
by SEC-MALS. ANKS6-SAM containing the R823W mutation is slightly
unfolded compared to ANKS6-SAM wt, as evidenced by the faster migration
on SEC-MALS and the slightly increased molecular mass: 8.4 kDa for
ANKS6-SAM R823W versus 7.8 kDa for ANKS6-SAM wt. This apparent
increase in molecular mass is consistent with a protein that is partially
unfolded and therefore exhibits a larger radius of gyration.Abbreviations
ADPKD: Autosomal dominant polycystic kidney disease; ANKS3: Ankyrin
repeat and SAM-domain containing protein 3; ANKS6: Ankyrin repeat and
SAM-domain containing protein 6; Bicc1: Bicaudal C homolog 1;
DGKδ: Diacylglycerol kinase delta; EH: End-helix; ML: Mid-loop; negGFP: Green
fluorescent protein with a net charge of −30; PKD: Polycystic kidney disease;
RXR: Retinoid X receptor; SEC-MALS: Size exclusion chromatography with inline
multi-angle light scattering; Shank3: SH3 and multiple ankyrin repeat domains
protein 3; SUMO: Small ubiquitin-like modifier; TEM: Transmission electron
microscopy.
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